Table 1 Subjects characteristics.
HV (n = 25) | SSc (n = 15) | SSc-ILD (n = 10) | |
|---|---|---|---|
Age, years | 57 ± 10 | 60 ± 11 | 57 ± 11 |
Gender (M/F) | 8/17 | 3/12 | 1/9 |
BMI, kg/m² | 27 ± 5 | 26 ± 5 | 25 ± 5 |
Smokers (NS/FS/S) | 11/9/5 | 8/4/3 | 3/5/2 |
FEV-1 post-BD, %pred. | 104 ± 15 | 89 ± 19* | 80 ± 18** |
FVC post-BD, %pred. | 110 ± 17 | 90 ± 13*** | 82 ± 17*** |
TLC, %pred. | nd | 90 ± 11 | 84 ± 19 |
DLCO %pred. | nd | 66 ± 16 | 55 ± 15 |
KCO %pred. | nd | 81 ± 21 | 71 ± 16 |
Immunosupressor yes/no | nd | 4/11 | 6/4 |
OCS yes/no | nd | 1/14 | 3/7 |
Disease duration in years | nd | 2 (6–20) | 0.75 (4–9) |
Rodnan skin score | nd | 3.6 (0–21) | 10.5 (1–25) |
ACR/Eular score | nd | 8 (6–13) | 12 (9.5–18) |
limited SSc/lcSSc/dcSSc/sine scleroderma (n) | nd | 5/9/0/1 | 1/5/4/0 |
Musculoskeletal involvement | nd | 1 | 0 |
Renal crisis | nd | 1 | 0 |
Cardiac involvement | nd | 0 | 0 |
Pulmonary arterial hypertension (n) | nd | 2 | 1 |
Characterization of ANA (number in %) | |||
Anti-SCl70 | nd | 2 (13%) | 5 (50%) |
Anti-centromere | nd | 9 (61%) | 2 (20%) |
Speckled | nd | 1 (6.5%) | 2 (20%) |
Nucleolar | nd | 2 (13%) | 1 (10%) |
Homogeneous | nd | 1 (6.5%) | 0 |
